VistaGen Therapeutics, Inc.(Exact name of small business issuer as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
205093315
(IRS Employer Identification No.)
384 Oyster Point Blvd, No. 8, South San Francisco, California 94080
(Address of principal executive offices)
650-244-9990
(Registrant's Telephone number)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On February 14, 2012, VistaGen Therapeutics, Inc. (the "Company") announced that the Company has identified its initial Top 10 drug rescue candidates and plans to launch two formal drug rescue programs by the end of next quarter. A copy of the press release is attached to this Current Report Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
See Item 8.01.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VistaGen Therapeutics, Inc.
|
Date: February 16, 2012
| By: |
/s/ Shawn Singh |
|
| Name: Shawn Singh |
| Title: Chief Executive Officer |
Exhibit Index
|
Exhibit No.
|
|
Description
|
|
EX-99.1
|
|
Press Release, Feb 14 2012
|